Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Kidney Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology
Robert J. Motzer, Eric Jonasch, Neeraj Agarwal, et al.
Journal of the National Comprehensive Cancer Network (2022) Vol. 20, Iss. 1, pp. 71-90
Open Access | Times Cited: 452

Showing 1-25 of 452 citing articles:

Prognostic and predictive biomarkers for immunotherapy in advanced renal cell carcinoma
Matteo Rosellini, Andrea Marchetti, Veronica Mollica, et al.
Nature Reviews Urology (2022) Vol. 20, Iss. 3, pp. 133-157
Closed Access | Times Cited: 144
Adjuvant nivolumab plus ipilimumab versus placebo for localised renal cell carcinoma after nephrectomy (CheckMate 914): a double-blind, randomised, phase 3 trial
Robert J. Motzer, Paul Russo, Viktor Grünwald, et al.
The Lancet (2023) Vol. 401, Iss. 10379, pp. 821-832
Closed Access | Times Cited: 112
Belzutifan plus cabozantinib for patients with advanced clear cell renal cell carcinoma previously treated with immunotherapy: an open-label, single-arm, phase 2 study
Toni K. Choueiri, David F. McDermott, Jaime R. Merchan, et al.
The Lancet Oncology (2023) Vol. 24, Iss. 5, pp. 553-562
Closed Access | Times Cited: 58
Pembrolizumab Plus Axitinib Versus Sunitinib as First-line Treatment of Advanced Renal Cell Carcinoma: 43-month Follow-up of the Phase 3 KEYNOTE-426 Study
Elizabeth R. Plimack, Thomas Powles, V.P. Stus, et al.
European Urology (2023) Vol. 84, Iss. 5, pp. 449-454
Closed Access | Times Cited: 55
Stereotactic body radiotherapy for primary renal cell carcinoma: a systematic review and practice guideline from the International Society of Stereotactic Radiosurgery (ISRS)
Shankar Siva, Alexander V. Louie, Rupesh Kotecha, et al.
The Lancet Oncology (2024) Vol. 25, Iss. 1, pp. e18-e28
Closed Access | Times Cited: 34
CD70-Targeted Allogeneic CAR T-Cell Therapy for Advanced Clear Cell Renal Cell Carcinoma
Sumanta K. Pal, Ben Tran, John B.A.G. Haanen, et al.
Cancer Discovery (2024) Vol. 14, Iss. 7, pp. 1176-1189
Open Access | Times Cited: 32
Cabozantinib and nivolumab with or without live bacterial supplementation in metastatic renal cell carcinoma: a randomized phase 1 trial
Hedyeh Ebrahimi, Nazlı Dizman, Luís Meza, et al.
Nature Medicine (2024) Vol. 30, Iss. 9, pp. 2576-2585
Open Access | Times Cited: 23
[89Zr]Zr-girentuximab for PET–CT imaging of clear-cell renal cell carcinoma: a prospective, open-label, multicentre, phase 3 trial
Brian Shuch, Allan J. Pantuck, Jean‐Christophe Bernhard, et al.
The Lancet Oncology (2024) Vol. 25, Iss. 10, pp. 1277-1287
Open Access | Times Cited: 22
Renal Cell Carcinoma
Tracy L. Rose, William Y. Kim
JAMA (2024) Vol. 332, Iss. 12, pp. 1001-1001
Closed Access | Times Cited: 18
Role of natural products in tumor therapy from basic research and clinical perspectives
Zhisen Wang, Zhengcheng Liu, Jiao Qu, et al.
Acta Materia Medica (2024) Vol. 3, Iss. 2
Open Access | Times Cited: 16
Results of Stereotactic Body Radiation Therapy for Primary Renal Cell Carcinoma in a Large Multicenter Series
Ludwige Abancourt, Muhammad Ali, Magali Quivrin, et al.
European Urology Oncology (2025)
Closed Access | Times Cited: 1
Health-related quality-of-life outcomes in patients with advanced renal cell carcinoma treated with lenvatinib plus pembrolizumab or everolimus versus sunitinib (CLEAR): a randomised, phase 3 study
Robert J. Motzer, Camillo Porta, B. Yа. Alekseev, et al.
The Lancet Oncology (2022) Vol. 23, Iss. 6, pp. 768-780
Open Access | Times Cited: 49
A multicenter phase 2 single arm study of cabozantinib in patients with advanced or unresectable renal cell carcinoma pre-treated with one immune-checkpoint inhibitor: The BREAKPOINT trial (Meet-Uro trial 03)
Giuseppe Procopio, Mélanie Claps, Chiara Pircher, et al.
Tumori Journal (2022) Vol. 109, Iss. 1, pp. 129-137
Open Access | Times Cited: 41
Micropeptide MIAC inhibits the tumor progression by interacting with AQP2 and inhibiting EREG/EGFR signaling in renal cell carcinoma
Mengwei Li, Guang‐Xiang Liu, Xinrong Jin, et al.
Molecular Cancer (2022) Vol. 21, Iss. 1
Open Access | Times Cited: 39
EHBP1L1 Drives Immune Evasion in Renal Cell Carcinoma through Binding and Stabilizing JAK1
Yihui Pan, Guannan Shu, Liangmin Fu, et al.
Advanced Science (2023) Vol. 10, Iss. 11
Open Access | Times Cited: 25
First-line therapy for adults with advanced renal cell carcinoma: a systematic review and network meta-analysis
Angela Aldin, Burcu Besiroglu, Anne Adams, et al.
Cochrane library (2023) Vol. 2023, Iss. 5
Open Access | Times Cited: 24
Radical Nephrectomy for Renal Cell Carcinoma
Joshua Cabral, Ardy Sowe, Vanessa Aponte, et al.
Springer eBooks (2023), pp. 91-109
Closed Access | Times Cited: 22
Ablative Treatments for Small Renal Masses and Management of Recurrences: A Comprehensive Review
Achille Aveta, Vincenzo Iossa, Gianluca Spena, et al.
Life (2024) Vol. 14, Iss. 4, pp. 450-450
Open Access | Times Cited: 14
Novel small molecule inhibitors targeting renal cell carcinoma: Status, challenges, future directions
Lin Xiong, Ya Zhang, Jiaxing Wang, et al.
European Journal of Medicinal Chemistry (2024) Vol. 267, pp. 116158-116158
Open Access | Times Cited: 10
Perioperative Complications and In-Hospital Mortality in Partial and Radical Nephrectomy Patients with Heart-Valve Replacement
Carolin Siech, Andrea Baudo, Mario de Angelis, et al.
Annals of Surgical Oncology (2024) Vol. 31, Iss. 8, pp. 5449-5456
Open Access | Times Cited: 10
Combination of bulk RNA sequencing and scRNA sequencing uncover the molecular characteristics of MAPK signaling in kidney renal clear cell carcinoma
Xiunan Li, Hewen Guan, Chuanyu Ma, et al.
Aging (2024) Vol. 16, Iss. 2, pp. 1414-1439
Open Access | Times Cited: 9
Updated systematic review and network meta-analysis of first-line treatments for metastatic renal cell carcinoma with extended follow-up data
Takafumi Yanagisawa, Keiichiro Mori, Akihiro Matsukawa, et al.
Cancer Immunology Immunotherapy (2024) Vol. 73, Iss. 2
Open Access | Times Cited: 9
The evolving management of small renal masses
Yuzhi Wang, Mohit Butaney, Samantha Wilder, et al.
Nature Reviews Urology (2024) Vol. 21, Iss. 7, pp. 406-421
Closed Access | Times Cited: 8
Does the Timing of Cytoreductive Nephrectomy Impact Outcomes? Analysis of REMARCC Registry Data for Patients Receiving Tyrosine Kinase Inhibitor Versus Immune Checkpoint Inhibitor Therapy
Margaret Meagher, Andrea Minervini, Maria Carmen Mir, et al.
European Urology Open Science (2024) Vol. 63, pp. 71-80
Open Access | Times Cited: 8
Histopathology based AI model predicts anti-angiogenic therapy response in renal cancer clinical trial
Jay Jasti, Hua Zhong, Vandana Panwar, et al.
Nature Communications (2025) Vol. 16, Iss. 1
Open Access | Times Cited: 1
Page 1 - Next Page

Scroll to top